Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease

被引:23
作者
Laheij, RJF
Jansen, JBMJ
Verbeek, ALM
Verheugt, FWA
机构
[1] Univ Nijmegen Hosp, Dept Gastroenterol, Nijmegen, Netherlands
[2] Univ Nijmegen, Dept Epidemiol, Nijmegen, Netherlands
[3] Univ Nijmegen Hosp, Ctr Heart, Div Cardiol, Nijmegen, Netherlands
关键词
D O I
10.1046/j.1365-2036.2001.01016.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Aspirin use in the secondary prevention of ischaemic heart disease may provoke gastrointestinal discomfort. Objective: To register gastrointestinal symptoms and complications in patients with cardiovascular disease using aspirin and to relate these symptoms to infection with H. pylori. Methods: Blood samples were obtained from 398 consecutive patients in the Coronary-Care Unit, University Hospital Nijmegen and analysed for serum antibody levels to H. pylori infection. Questionnaires were sent 2 weeks after discharge to assess gastrointestinal symptoms. Results: Questionnaires were returned by 314 patients (79%). A total of 183 out of 314 patients (46%) reported gastrointestinal symptoms. Of 238 patients using 80-100 mg aspirin daily, 145 (61%) recorded gastrointestinal symptoms. Besides aspirin, the use of calcium antagonists was correlated with gastrointestinal symptoms, Of the 128 patients using calcium antagonists, 84 (66%) reported gastrointestinal symptoms. The prevalence of gastrointestinal symptoms in H. pylori-positive and -negative patients using aspirin was 48% and 52%, respectively. Conclusions: Two weeks after discharge almost 50% of the patients with cardiovascular disease experienced gastrointestinal symptoms, especially patients using aspirin or calcium antagonists. Patients seropositive for H. pylori and using aspirin or calcium antagonists did not have more gastrointestinal discomfort compared to non-infected patients.
引用
收藏
页码:1055 / 1059
页数:5
相关论文
共 16 条
[1]  
[Anonymous], 1994, NIH Consens Statement, V12, P1
[2]   Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers [J].
Chan, FKL ;
Sung, JJY ;
Chung, SCS ;
To, KF ;
Yung, MY ;
Leung, VKS ;
Lee, YT ;
Chan, CSY ;
Li, EKM ;
Woo, J .
LANCET, 1997, 350 (9083) :975-979
[3]  
GARCIARODRIGUEZ LA, 1988, ARCH INTERN MED, V158, P33
[4]   Major upper gastrointestinal bleeding and the use of calcium channel blockers [J].
Kelly, JP ;
Laszlo, A ;
Kaufman, DW ;
Sundstrom, A ;
Shapiro, S .
LANCET, 1999, 353 (9152) :559-559
[5]   Diagnostic performance of biopsy-based methods for determination of Helicobacter pylori infection without a reference standard [J].
Laheij, RJF ;
de Boer, WA ;
Jansen, JBMJ ;
van Lier, HJJ ;
Sneeberger, PM ;
Verbeek, ALM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2000, 53 (07) :742-746
[6]   Evaluation of commercially available Helicobacter pylori serology kits:: a review [J].
Laheij, RJF ;
Straatman, H ;
Jansen, JBMJ ;
Verbeek, ALM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2803-2809
[7]   Evidence of aspirin use in both upper and lower gastrointestinal perforation [J].
Lanas, A ;
Serrano, P ;
Bajador, E ;
Esteva, F ;
Benito, R ;
Sainz, R .
GASTROENTEROLOGY, 1997, 112 (03) :683-689
[8]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS - THE CLINICAL DILEMMAS [J].
MCCARTHY, DM .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 :9-16
[9]  
Meade TW, 1998, LANCET, V351, P233
[10]   Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old [J].
Pahor, M ;
Guralnik, JM ;
Furberg, CD ;
Carbonin, P ;
Havlik, RJ .
LANCET, 1996, 347 (9008) :1061-1065